SMARCB1/INI1 expression in CRC and its impact on patients’ survival. (A) Overall survival (OS) referred to all tumor stages (I-IV) is estimated using the Kaplan–Meier method and stratifying the patients according to three categories of SMARCB1/INI1 expression (Neg, Low, High). (B) The same Kaplan-Meier survival analysis is carried out taking into account only tumor stages I-II. (C) Mean survival time referred to the three categories of SMARCB1/INI1 expression and stratified according to the mismatch repair (MMR) status. MMR (+) and MMR (−) indicate MMR proficient and deficient tumors, respectively. p <0.01. The p value is reported in each graph.